Study analysis · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025
This diet helped 71% of ulcerative colitis patients quit steroids—without losing weight.
A short, low-calorie plant-based diet didn't cure more people with ulcerative colitis, but it made them feel way better and helped most stop taking steroids.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study is like a fair test where some people ate a special diet and others didn’t, and then doctors checked if they felt better. It found that those on the diet felt a little better on average, but the results weren’t strong enough to say for sure the diet caused it. So we can’t say the diet definitely helps, but it might.
What’s the bottom line?
People with active ulcerative colitis tried a special low-calorie plant-based diet for 5 days, twice, while starting new medications. Another group ate normally based on what felt okay.
How strong is this study?
The study tried to be fair by randomly assigning people to groups and using good tools to measure symptoms. But it only had a few people, and it got interrupted by the pandemic, so we can’t be super sure the results aren’t just luck. That’s why we need bigger studies to trust it more.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
71 / 100
- Randomization+20/20
- Blinding+9/15
- Control group+15/15
- Sample size (n=32)+3.0/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 564 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Although this is a randomized controlled trial, the small sample size (n=32, planned n=60) and early termination due to COVID-19 limit statistical power and increase risk of chance findings, reducing confidence in causal conclusions despite randomization.
Major COI
Major conflicts that significantly reduce study credibility
The study used commercially available diet kits from ProLonLife.com, a company with a financial interest in the product being tested, and provided the kits at no cost to participants, indicating industry support that could influence study outcomes.
Funders
Conflict Details
ProLonLife.com: Provided commercial diet kits at no cost to participants for the intervention arm; diet protocol aligned with company's proprietary fasting-mimicking diet design.
The study did not disclose funding sources or a conflict of interest statement. The provision of proprietary diet kits by ProLonLife.com, combined with the alignment of the intervention design with their product, raises concerns about potential bias in study design and interpretation. No independent oversight of data analysis or publication decisions is mentioned.
Key takeaways
- 01
The fasting diet didn't make more people go into remission (57% vs 35%), but it did reduce symptoms more (SCCAI dropped 2.81 points more), helped 71% stop steroids (vs 11%), lowered inflammation markers, and raised ketones without weight loss.
- 02
Even though it didn't cure more people, it made symptoms feel better, helped patients stop steroid pills, and reduced body-wide inflammation — which matters a lot for quality of life.
Surprising findings
- The diet didn’t cause weight loss despite being low-calorie.Most low-calorie diets lead to weight loss, especially in overweight individuals. Here, participants maintained weight while reducing inflammation and steroid use.
- The primary endpoint (clinical response) wasn’t met, but every secondary outcome was positive.In clinical trials, if the main goal fails, the study is often dismissed. Here, every secondary measure—symptom reduction, steroid tapering, SAA drop—was statistically significant.
- Ketosis was achieved with only 54.77g of non-fiber carbs—close to the 50g threshold.Most people think you need to eat almost zero carbs to enter ketosis. This shows a plant-based, fiber-rich diet can trigger ketosis without extreme restriction.
Practical takeaways
If you have ulcerative colitis and are on steroids, ask your doctor about a supervised 5-day low-calorie, plant-based fasting-mimicking diet cycle to help reduce steroid dependence.
This was tested in a small, supervised trial with medical oversight. Do not attempt without professional guidance, especially if underweight or malnourished.
medium confidenceTrack your symptoms with the SCCAI scale (urgency, well-being, bleeding) instead of waiting for a doctor’s remission label—improvement matters even without full remission.
SCCAI is not widely used outside research; ask your GI for a symptom tracker or use apps like MyIBD.
high confidenceIf you’re trying intermittent fasting for inflammation, focus on plant-based, fiber-rich, low-nonfiber-carb meals—54g or less may be enough to trigger ketosis.
This diet was 725–1090 kcal/day for 5 days. It’s not a long-term solution and may not be suitable for everyone.
medium confidenceWhy this study matters
Steroid-Free Success
71% of participants on the fasting-mimicking diet stopped using corticosteroids within 8 weeks, compared to just 11% in the control group (p=0.03). This happened without weight loss or serious side effects.
Steroids are a common but risky treatment for ulcerative colitis—long-term use causes bone loss, diabetes, and mood swings. This diet offers a natural way to reduce dependence.
Symptoms Improved—But Not Remission
While the diet didn’t significantly increase the number of people reaching clinical remission (57% vs 35%, p=0.11), it caused a statistically significant 2.81-point greater drop in symptom scores (SCCAI) compared to controls (p=0.039).
Most people care more about feeling better day-to-day than hitting a clinical benchmark. This diet improved urgency, well-being, and discomfort—even if it didn’t ‘cure’ them.
Ketosis Without Weight Loss
Beta-hydroxybutyrate—a ketone linked to anti-inflammatory effects—rose from 0.08 to 0.33 mmol/L in the diet group (p=0.031), yet participants didn’t lose weight. This suggests metabolic benefits independent of calorie restriction.
People think fasting = weight loss. This shows you can trigger powerful anti-inflammatory biology without shedding pounds.
The Hidden Inflammation Marker
Serum amyloid A (SAA), a more sensitive inflammation marker than CRP, dropped significantly in the diet group (p=0.047). This matters because SAA detects inflammation even when CRP is normal.
Doctors often rely on CRP—but this study shows SAA might be the real early warning system for gut inflammation.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
People with active ulcerative colitis tried a special low-calorie plant-based diet for 5 days, twice, while starting new medications. Another group ate normally based on what felt okay.
Research results
The fasting diet didn't make more people go into remission (57% vs 35%), but it did reduce symptoms more (SCCAI dropped 2.81 points more), helped 71% stop steroids (vs 11%), lowered inflammation markers, and raised ketones without weight loss.
What this means - more context
Even though it didn't cure more people, it made symptoms feel better, helped patients stop steroid pills, and reduced body-wide inflammation — which matters a lot for quality of life.
This pilot randomized controlled trial examined whether two cycles of a low-calorie, plant-based fasting-mimicking diet could improve response to advanced therapies in adults with active ulcerative colitis.
The diet did not significantly improve the primary endpoint of clinical response (SCCAI decrease ≥3), but it led to statistically significant improvements in continuous SCCAI reduction, steroid discontinuation, and serum amyloid A levels, with no weight loss or serious adverse events.
Methods Used
32 adults with active UC starting advanced therapies were randomized 1:1 to a 5-day low-calorie (1090/725 kcal), plant-based fasting-mimicking diet or a symptom-based control diet, with two cycles over 8 weeks. Primary endpoint: clinical response (SCCAI ≥3 reduction). Secondary outcomes: SCCAI change, steroid tapering, SAA, CRP, fecal calprotectin, and ketosis (beta-hydroxybutyrate). Intention-to-treat analysis with adjustment for covariates.
Main Finding
The low-calorie, plant-based fasting-mimicking diet did not significantly improve clinical response (57% vs. 35%; p=0.11), but significantly improved continuous SCCAI reduction (mean difference −2.81; 95% CI: −5.58 to −0.03; p=0.039), increased steroid discontinuation (71% vs. 11%; p=0.03), and reduced serum amyloid A (p=0.047), with a significant increase in beta-hydroxybutyrate (p=0.031).
Confidence Level
Low to moderate; findings are limited by small sample size (n=32), early termination due to COVID-19, and underpowering for primary endpoint, though secondary outcomes show consistent, statistically significant effects with plausible biological mechanisms.
Study Flags
Red Flags
- •Small sample size (n=32)
- •Study terminated early due to COVID-19
- •Primary endpoint not met despite significant secondary outcomes
Surprising Findings
The diet didn’t cause weight loss despite being low-calorie.
Most low-calorie diets lead to weight loss, especially in overweight individuals. Here, participants maintained weight while reducing inflammation and steroid use.
Practical Takeaways
If you have ulcerative colitis and are on steroids, ask your doctor about a supervised 5-day low-calorie, plant-based fasting-mimicking diet cycle to help reduce steroid dependence.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 564 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study is like a fair test where some people ate a special diet and others didn’t, and then doctors checked if they felt better. It found that those on the diet felt a little better on average, but the results weren’t strong enough to say for sure the diet caused it. So we can’t say the diet definitely helps, but it might.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Randomized controlled trial design with stratified randomization by medication class
- Intention-to-treat analysis performed
- Use of validated outcome measures (SCCAI)
Weaknesses
- Small sample size (n=32) with only 23 completers
- Study terminated early due to COVID-19, leading to underpowering
- Primary endpoint not statistically significant (p=0.11)
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
People with active ulcerative colitis tried a special low-calorie plant-based diet for 5 days, twice, while starting new medications. Another group ate normally based on what felt okay.
Research results
The fasting diet didn't make more people go into remission (57% vs 35%), but it did reduce symptoms more (SCCAI dropped 2.81 points more), helped 71% stop steroids (vs 11%), lowered inflammation markers, and raised ketones without weight loss.
What this means - more context
Even though it didn't cure more people, it made symptoms feel better, helped patients stop steroid pills, and reduced body-wide inflammation — which matters a lot for quality of life.
This pilot randomized controlled trial examined whether two cycles of a low-calorie, plant-based fasting-mimicking diet could improve response to advanced therapies in adults with active ulcerative colitis.
The diet did not significantly improve the primary endpoint of clinical response (SCCAI decrease ≥3), but it led to statistically significant improvements in continuous SCCAI reduction, steroid discontinuation, and serum amyloid A levels, with no weight loss or serious adverse events.
Methods Used
32 adults with active UC starting advanced therapies were randomized 1:1 to a 5-day low-calorie (1090/725 kcal), plant-based fasting-mimicking diet or a symptom-based control diet, with two cycles over 8 weeks. Primary endpoint: clinical response (SCCAI ≥3 reduction). Secondary outcomes: SCCAI change, steroid tapering, SAA, CRP, fecal calprotectin, and ketosis (beta-hydroxybutyrate). Intention-to-treat analysis with adjustment for covariates.
Main Finding
The low-calorie, plant-based fasting-mimicking diet did not significantly improve clinical response (57% vs. 35%; p=0.11), but significantly improved continuous SCCAI reduction (mean difference −2.81; 95% CI: −5.58 to −0.03; p=0.039), increased steroid discontinuation (71% vs. 11%; p=0.03), and reduced serum amyloid A (p=0.047), with a significant increase in beta-hydroxybutyrate (p=0.031).
Confidence Level
Low to moderate; findings are limited by small sample size (n=32), early termination due to COVID-19, and underpowering for primary endpoint, though secondary outcomes show consistent, statistically significant effects with plausible biological mechanisms.
Study Flags
Red Flags
- •Small sample size (n=32)
- •Study terminated early due to COVID-19
- •Primary endpoint not met despite significant secondary outcomes
Surprising Findings
The diet didn’t cause weight loss despite being low-calorie.
Most low-calorie diets lead to weight loss, especially in overweight individuals. Here, participants maintained weight while reducing inflammation and steroid use.
Practical Takeaways
If you have ulcerative colitis and are on steroids, ask your doctor about a supervised 5-day low-calorie, plant-based fasting-mimicking diet cycle to help reduce steroid dependence.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 564 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study is like a fair test where some people ate a special diet and others didn’t, and then doctors checked if they felt better. It found that those on the diet felt a little better on average, but the results weren’t strong enough to say for sure the diet caused it. So we can’t say the diet definitely helps, but it might.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Randomized controlled trial design with stratified randomization by medication class
- Intention-to-treat analysis performed
- Use of validated outcome measures (SCCAI)
Weaknesses
- Small sample size (n=32) with only 23 completers
- Study terminated early due to COVID-19, leading to underpowering
- Primary endpoint not statistically significant (p=0.11)
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study tried to be fair by randomly assigning people to groups and using good tools to measure symptoms. But it only had a few people, and it got interrupted by the pandemic, so we can’t be super sure the results aren’t just luck. That’s why we need bigger studies to trust it more.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
71 / 100
- Randomization+20/20
- Blinding+9/15
- Control group+15/15
- Sample size (n=32)+3.0/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 564 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Although this is a randomized controlled trial, the small sample size (n=32, planned n=60) and early termination due to COVID-19 limit statistical power and increase risk of chance findings, reducing confidence in causal conclusions despite randomization.
Major COI
Major conflicts that significantly reduce study credibility
The study used commercially available diet kits from ProLonLife.com, a company with a financial interest in the product being tested, and provided the kits at no cost to participants, indicating industry support that could influence study outcomes.
Funders
Conflict Details
ProLonLife.com: Provided commercial diet kits at no cost to participants for the intervention arm; diet protocol aligned with company's proprietary fasting-mimicking diet design.
The study did not disclose funding sources or a conflict of interest statement. The provision of proprietary diet kits by ProLonLife.com, combined with the alignment of the intervention design with their product, raises concerns about potential bias in study design and interpretation. No independent oversight of data analysis or publication decisions is mentioned.